$GENB News

Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22

HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25

Generate Biomedicines Q1 EPS $(1.07) Misses $(0.54) Estimate, Sales $7.224M Beat $5.938M Estimate

Generate Biomedicines shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a price target of $16.

Generate Biomedicines shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a price target of $16.

HC Wainwright & Co. Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $16

Goldman Sachs Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $26

Morgan Stanley Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $20

Piper Sandler Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $24

Cantor Fitzgerald Initiates Coverage On Generate Biomedicines with Overweight Rating

Guggenheim Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $30

Generate Biomedicines Opens For Trade At $15/Share; IPO Priced At $16/Share On 25M Shares

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Reported Earlier, Generate Biomedicines Prices Initial Public Offering Of 25M Shares At $16.00 Per Share, Raising $400M In Gross Proceeds

Preview: Generate Biomedicines, Inc Set To IPO Tomorrow

Generate Biomedicines Begins IPO Push With Major Collaboration Deals